Introduction
Human immunodeficiency virus (HIV)-infected patients are at increased risk of developing non-Hodgkin Lymphoma (NHL) when compared to the general population , . In the 1980s the risk of NHL within three years of an AIDS diagnosis was increased 165-fold [1 2 ] when compared to people without AIDS . Following its introduction in 1996, combination antiretroviral therapy (cART) has led to a [3 ] substantial reduction in HIV-associated morbidity and mortality; however, cohort studies have shown that the decline in the incidence of NHL in the cART era was less pronounced than that observed for Kaposi s Sarcoma (KS) or opportunistic infections . Consequently ' [4 -7 ] NHL has become one of the most frequent AIDS-defining events in recent years and the most common cancer associated with HIV in [8 ] the USA . In HIV-infected patients NHL poses particular therapeutic challenges and continues to be an important cause of death in [7 ] [9 ]
the era of cART . [10 ] Previous studies showed that the risk of NHL in HIV-infected persons is increased in older patients , in patients with more [11 -14 ] advanced immunodeficiency and patients with high HIV-1 viral loads , . Many of these studies were, however, from the [11 -15 ] [11 14 ] pre-cART era or lacked information on cART at the patient level
. Only a few, relatively small studies specifically addressed risk [16 ] factors for NHL in patients receiving cART , , . [11 13 14 ] We analyzed the database of the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) to examine the incidence and risk factors of NHL in the cART era.
Methods
COHERE is a collaboration of 33 observational cohort studies in 30 European countries . COHERE was established in 2005 with [17 ] the objective of conducting hypothesis-driven research on the prognosis and outcome of HIV-infected individuals across Europe. All cohorts have been approved by local ethics committees or institutional review boards, use standardized methods of data collection, and schedule follow-up visits at least once every 6 months. Each cohort submits information using the standardized HIV Collaboration Data
Exchange Protocol (HICDEP) to co-ordinating centres at the Copenhagen HIV Program (CHIP), Copenhagen, Denmark, or the [18 ] Institut 
Inclusion criteria and definitions
We included all adult (aged 16 years or older) antiretroviral treatment-na ve HIV-infected patients enrolled in COHERE cohorts who ï started cART at some point after 1 January 1998, at a time when cART had become well established and widely used in Europe. All patients had to have at least one CD4 cell measurement after enrolment and before starting cART. In patients developing NHL, the CD4 count had to be measured before the diagnosis of NHL. Baseline CD4 cell count was defined as the first CD4 count measured during a visit after 1 January 1998. The baseline HIV-1 RNA was taken as the measurement closest to the baseline CD4 cell count, within a window of plus or minus 30 days not on cART. The nadir CD4 cell count was defined as the lowest ever measured CD4 cell count up to seven days after starting cART. In patients who developed NHL before starting cART, the nadir CD4 count had to be measured before the diagnosis of NHL. We defined cART as a regimen with at least 3 antiretroviral drugs from any drug class, including protease inhibitors (PIs), nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs) and fusion inhibitors.
Data were merged on 31 July 2006.
The diagnosis of NHL was made on the basis of the 1993 CDC (Centers for Disease Control and Prevention) histology criteria .
model based on biological and statistical reasoning; no automated selection procedure was applied. The effect of changes in CD4 cell counts and plasma HIV-1 RNA load over time were explored in time-updated models. 
Results

Characteristics of cohorts and patients
The database included a total of 67,659 patients, including 1,176 patients who had been diagnosed with NHL. Of note, among patients with NHL, 660 (56.1 ) had been diagnosed while not on cART. A total of 11,354 (16.8 ) patients were excluded from the analysis for % % the reasons detailed in . The most important reasons for exclusion were missing CD4 counts between 01.01.1998 and the start of Figure 1 cART or the diagnosis of NHL. Of note, this group included many patients who were diagnosed with NHL and enrolled in the cohort around the same time, i.e. patients with prevalent NHL. Patients not diagnosed with NHL and excluded because of missing CD4 counts were more likely to have a history of intravenous drug use (27 versus 17 ) and of AIDS compared to included patients (26 versus 18 % % % % ); patients were similar with respect to age and gender. Among patients with NHL those who were excluded had more often been diagnosed with AIDS before developing NHL compared to included patients (22 versus 14 ), but they were similar with respect to age, Table 1 patients were male (n 40,350, 72 ). Overall, heterosexual contacts were the most frequent risk factor for HIV transmission, followed by patients who did not develop NHL, patients diagnosed with NHL were older, more likely to be male, and more likely to be in more advanced stages of the infection, with lower CD4 cell counts and higher plasma HIV-1 RNA loads at baseline ( ). Patients on Table 1 cART at the time of systemic NHL diagnosis were more often in advanced clinical stage (26 versus 12 in CDC clinical stage C) and % % had lower CD4 cell counts (median 164 cells/ L versus 187 cells/ L) compared to cART na ve patients. As expected, patients who had not μ μ ï been on cART had higher HIV-1 RNA viral loads ( ). Table 4 Incidence of NHL while not on cART and on cART A total of 155 systemic NHL were diagnosed while not on cART and 366 were diagnosed on cART. The incidence rate was 462. 6 100,000 person-years on cART, for a rate ratio of 0.43 (95 CI 0.25 to 0.73). Overall the median time from the start of observation to the % diagnosis was 81 days (IQR 18 to 707 days) while not on cART, and 287 days (IQR 82 860 days) while on cART. In sensitivity analyses -incidence rates were similar when including the patients with missing CD4 counts, but excluding prevalent cases. shows that Figure 2 incidence rates for any type of NHL declined with increasing nadir CD4 counts and decreasing baseline HIV-1 RNA viral load. These trends were particularly pronounced in patients not on cART.
shows the cumulative incidence of any NHL (systemic NHL and Figure 3 PBL) after start of cART by nadir CD4 cell count. Overall 1.21 (95 CI 1.09 1.34 ) of patients had developed a systemic NHL or 4 11 In
a difference in risk across cART regimens (PI-based, NNRTI-based or NRTIs only).
Discussion
The incidence of HIV-associated NHL in patients receiving cART was lower than in patients not on cART, with reductions in incidence rate of over 50 both for systemic NHL and PBL. A history of advanced immunodeficiency and older age were associated with % an increased risk of systemic NHL both in patients receiving and not receiving cART. In patients on cART, a prior diagnosis of KS and transmission through sex between men was also associated with NHL. Exposure to high plasma HIV-1 RNA concentrations and low CD4 cell counts were risk factors in patients not receiving cART. Conversely, suppression of HIV-1 replication and immune recovery were protective factors in patients receiving cART. Our results thus support the notion that both immunodeficiency and replication of HIV-1 play a role in the development of NHL , , . [13 14 23 ] Our study has several limitations. The analysis was restricted to patients with CD4 cell counts available before the start of cART and prior to the diagnosis of NHL. This meant that some patients were excluded from the analysis, although incidence rates were similar when they were included in sensitivity analyses. In the majority of cases the histological subtype was not specified and we could therefore only distinguish between systemic NHL and PBL. The number of patients developing PBL was small even in this large collaborative study.
Finally, cART na ve patients who developed NHL and died before starting cART were not included in the present data set. This may have ï lead to an underestimation of the incidence rate of NHL in patients not on cART. On the other hand, our analysis of patients on cART may have included periods where cART was interrupted, leading to overestimation of the incidence rate of NHL on cART.
Previous studies have shown a decline in the incidence of HIV-related NHL when comparing the pre-cART and cART eras , . [15 24 ] The interpretation of these comparisons is, however, not straightforward because the treatment status of the individual patient was not known , . As our study shows, the availability of cART does not mean that all patients actually receive cART: in our study about 50 [15 24 ] of patients (before exclusions) were not on cART when diagnosed with NHL. Similar data were reported both in other cohort studies
and clinical trials .
Our data confirm that exposure to low CD4 cell counts is the main risk factor for developing NHL but within categories of [11 -15 ] similar CD4 cell nadirs, cART treated patients had a lower risk of NHL compared to patients not on cART. Of note, a diagnosis of AIDS was not associated with an increased risk of NHL after adjusting for nadir CD4 cells count. However, we found that a history of KS was a significant risk factor in patients on cART, after adjusting for transmission group and other risk factors in multivariable analysis.
Pathways that may be involved in the development of lymphoma in HIV-infected patients include immunosuppression, chronic B-cell stimulation and transformation caused by other co-infecting viruses, such as Epstein Barr virus (EBV) and human herpes virus 8 (HHV-8)
. The association between HHV-8 and KS, and the rare multicentric Castleman disease and primary effusion lymphoma is well [29 -32 ] established while a possible association with other lymphoproliferative disorders is a matter of ongoing debate . Results from [32 -37 ] previous studies suggested an increased risk of specific subtypes of NHL in HIV-infected patients diagnosed with KS , , . [20 21 38 -41 ] Our results provide some support for the hypothesis that HHV-8 may contribute to the development of NHL. However, patients with a malignant disease are generally at increased risk of developing secondary NHL and other malignancies, which may be related to exposure to chemotherapy and genetic factors . Further studies are needed to clarify a possible role of HHV-8 and specific subtypes of In conclusion, the risk of HIV-related NHL is more than halved in patients on cART. Timely initiation of cART followed by suppression of HIV replication and immune recovery are key factors to prevent NHL in the era of cART. The association with Kaposi
Sarcoma suggests a role of HHV-8 in HIV-associated NHL, which needs further investigation. 5 11
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Figure 1
Identification of study population
Figure 2
Incidence rate of any type of non-Hodgkin lymphoma (systemic NHL and PBL) across categories of baseline CD4 cell count (upper panel) and HIV-1 viral load (lower panel) in patients on cART and not on cART
Figure 3
Cumulative incidence of any type of non-Hodgkin lymphoma (systemic NHL and PBL) in patients on cART by nadir CD4 cell count All variables except nadir CD4 count were measured at baseline for the analysis of patients not on cART and at the start of cART for the analysis of patients on cART. 
